Conference Coverage

Apixaban prevails in study of 163,000 DOAC users

Publish date: April 16, 2018

 

REPORTING FROM ACC 2018

SOURCE: Deitelzweig SB. ACC 2018.

Pages

Recommended Reading

ODYSSEY Outcomes trial redefines secondary cardiovascular prevention
MDedge Family Medicine
Ticagrelor noninferior to clopidogrel in terms of major bleeds in STEMI
MDedge Family Medicine
Genotype did not significantly affect evacetrapib response
MDedge Family Medicine
CECCY: Carvedilol didn’t curb cardiotoxicity in breast cancer patients
MDedge Family Medicine
MDedge Daily News: Improving wearable cardioverter defibrillators
MDedge Family Medicine
MOMENTUM 3 HeartMate 3 LVAD ‘practice changing’
MDedge Family Medicine
Barbershop intervention cuts blood pressure in black men
MDedge Family Medicine
VIDEO: Patient vouchers prompt physicians to prescribe top antiplatelet drugs
MDedge Family Medicine
Statins, ACE inhibitors linked to fetal cardiac anomalies
MDedge Family Medicine
Cardiovascular risk in type 2 diabetes: Patients are often clueless
MDedge Family Medicine

Related Articles